Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateAug 7, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: filing, operations, financials

Related Tickers: LRMR

TL;DR

Larimar Therapeutics filed an 8-K on Aug 7th, updating investors on operations and financials.

AI Summary

Larimar Therapeutics, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, as well as other events and financial statements. The filing details the company's status and provides updates on its business operations. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing provides an official update on Larimar Therapeutics' operational and financial status, which is crucial for investors to understand the company's current standing.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting operational and financial status without immediate material changes or specific negative events disclosed in the excerpt.

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • August 07, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36510 (filing_id) — SEC File Number
  • 20-3857670 (tax_id) — IRS Employer Identification No.
  • Three Bala Plaza East, Bala Cynwyd, Pennsylvania 19004 (address) — Principal Executive Offices
  • ZAFGEN, INC. (company) — Former Company Name

FAQ

What is the primary purpose of this 8-K filing for Larimar Therapeutics, Inc.?

The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as Other Events and Financial Statements and Exhibits, as of August 7, 2024.

On what date was this 8-K filed?

The 8-K was filed on August 7, 2024.

In which U.S. state is Larimar Therapeutics, Inc. incorporated?

Larimar Therapeutics, Inc. is incorporated in Delaware.

What is Larimar Therapeutics' principal executive office address?

The principal executive office is located at Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania 19004.

Has Larimar Therapeutics, Inc. operated under any former names?

Yes, the company formerly operated under the names ZAFGEN, INC. and ZAFGEN INC.

Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-08-07 07:02:18

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 7, 2024, Larimar Therapeutics, Inc. (the " Company ") announced its financial results and operational highlights for the second quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On August 7, 2024, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on August 7, 2024* 99.2 Larimar Therapeutics, Inc. Corporate Presentation, dated August 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics. Inc. Date: August 7, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.